For the quarter ending 2025-09-30, SABSW made -$47,498,825 in revenue. $45,445,469 in net income. Net profit margin of -95.68%.
| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 8,970,010 | |||
| General and administrative | 3,708,959 | |||
| Total operating expenses | 12,678,969 | |||
| Loss from operations | -12,678,969 | |||
| Changes in fair value of warrant liabilities | -61,598,908 | |||
| Interest expense | 43,292 | |||
| Interest income | 655,233 | |||
| Other income | 765,881 | |||
| Warrant issuance cost | 4,852,292 | |||
| Total other income | 58,124,438 | |||
| Net income (loss) | 45,445,469 | |||
| Earnings per share, diluted, total | -0.21 | |||
| Net loss per share, basic | 0.5 | |||
| Weighted-average common shares outstanding - basic | 10,660,500 | |||
| Weighted-average common shares outstanding - diluted | 77,863,263 | |||
SAB Biotherapeutics, Inc. (SABSW)
SAB Biotherapeutics, Inc. (SABSW)